Omeros | OMER - Cash And Equivalent


Omeros reported $1.9M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Adma Biologics USD 138.15M 50.52M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Immunic USD 186.63M 171.15M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
MacroGenics USD 66.52M 9.3M Mar/2026
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 144.31M 14.24M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Rockwell Medical USD 12.48M 1.09M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
United Therapeutics USD 1.28B 277.4M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Xoma USD 143.9M 7.68M Jun/2024